References
- Mitchell GDB. Amyotrophic lateral sclerosis. Lancet Neurol. 2007;369:2031–41.
- Ludolph AC, Brettschneider J, Weishaupt JH. Amyotrophic lateral sclerosis. Curr Opin Neurol. 2012;25:530–5.
- Tokuda T. Biomarkers for amyotrophic lateral sclerosis. Brain Nerve. 2012;64:515–23.
- Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, McGrath M, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14 (Suppl 1):19–32.
- Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75–82.
- Chio A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73: 1681–5.
- Dedic SI, Stevic Z, Dedic V, Stojanovic VR, Milicev M, Lavrnic D. Is hyperlipidaemia correlated with longer survival in patients with amyotrophic lateral sclerosis? Neurol Res. 2012;34:576–80.
- Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258:613–7.
- Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidaemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004–9.
- Goldstein MR, Mascitelli L, Pezzetta F. Dyslipidaemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;71: 956; author reply, –7.
- Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51:1501–8.
- Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidaemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20–4.
- Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:638–42.
- Yang JW, Kim SM, Kim HJ, Kim JE, Park KS, Kim SH, et al. Hypolipidaemia in patients with amyotrophic lateral sclerosis: a possible gender difference? J Clin Neurol. 2013;9:125–9.
- Wei Q, Chen X, Zheng Z, Huang R, Guo X, Cao B, et al. Screening for cognitive impairment in a Chinese ALS population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:40–5.
- Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323–30.
- Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
- Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327: 557–60.
- Okamoto K, Kihira T, Kondo T, Kobashi G, Washio M, Sasaki S, et al. Nutritional status and risk of amyotrophic lateral sclerosis in Japan. Amyotroph Lateral Scler. 2007; 8:300–4.
- Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord. 2007;22:377–81.
- Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson’s disease patients: a case-control study. Stroke. 2006;37:1184–8.
- Miyake Y, Tanaka K, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, et al. Case-control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolaemia, and diabetes in Japan. J Neurol Sci. 2010;293:82–6.
- de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol. 2006;164:998–1002.
- Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolaemia, diabetes, and risk of Parkinson’s disease. Neurology. 2007;69:1688–95.
- Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson’s disease. Neurology. 2008;70:1972–9.
- Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004;101:11159–64.
- Kim SM, Kim H, Kim JE, Park KS, Sung JJ, Kim SH, et al. Amyotrophic lateral sclerosis is associated with hypolipidaemia at the presymptomatic stage in mice. PLoS One. 2011;6:e17985.
- Li JH, Wang LM, Li YC, Bi YF, Jiang Y, Mi SQ, et al. Epidemiological characteristics of dyslipidaemia in Chinese adults,2010. Zhonghua Yu Fang Yi Xue Za Zhi.2012; 46:414–8.